• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌细胞溶质中雌激素受体与孕激素受体浓度之比(按孕激素受体不同分组分层)。

Ratio of concentrations of estrogen receptors to progesterone receptors (ER/PR) in the cytosol of breast cancers (stratification by forming of groups differing in PR).

作者信息

Hochmann J

机构信息

Pharmaceutical faculty of Charles Universiy, Department of Biological and Medical Sciences, Heyrovskeho 1203, Czech Republic.

出版信息

Neoplasma. 2007;54(4):290-6.

PMID:17822318
Abstract

The ratio of cytosol concentrations of estrogen receptors to progesterone receptors (ER/PR) can help at the diagnosis of the excessive production of estrogens or (on the contrary) of the lowered function of ER or of the too small expression of the PR gene. We divided the statistical set into the groups with the approximately same concentrations of PR for stronger judgement of this ratio because PR is nearly not changing due to the age (in contrast to the age unstable ER). We used this stratification into the PR-limited groups at the radio-receptor analysis of 147 patients. 1) The ER/PR quotient was higher in the older patients but predominantly it was approximately 10-times lower in case of the high PR than in case of the low PR. This is why the more than 10-fould error can arise at uncorrected judgement whether ER of some patient is inadequately high or low in the comparison with her PR. It implies that e.g. in case of any one patient it is possible to infer the excessive production of ER from the comparison of her ER/PR--best only in the range of her PR-limited group (and in the addition taking account of the age). It can be important for therapy and prognosis. 2) The interpersonal differences of ER and ER/PR were approximately 10-times smaller in PR-limited groups than in the whole statistical set. This is why e.g. the correlation coefficients of the age increase of ER and ER/PR in the PR-limited groups were more favourable than in the whole non-stratified statistical set. In case if PR decreases in the higher age in case of some authors, it is necessary to create the PR-limited groups by another manner. For instance, 20 % of the tumors with the highest PR from each age group will be in the same PR-limited group (despite the fact that they differ in PR). The impact of the age will be then more marked in case of ER/PR than in case of ER only because the numerator elevates and denominator decreases. The impact of the ovarian cycle might be detected more sensitively on the same principle. It is possible to analyse by this manner the possibility to transform the receptor results to the average age or to the optimal phase of the ovulation cycle to prevent e.g. the false negativity of ER. The principles of this mathematical approach might be exploited even for a judgement of the prognosis and therapy on the basis of the mutual ratio of different isotypes of receptors for one hormone only (ERalpha / ERbeta or PRA / PRB). It concerns not only the breast cancers but also the cancers of the uterus.

摘要

雌激素受体与孕激素受体的胞浆浓度比值(ER/PR)有助于诊断雌激素过度产生,或者相反,有助于诊断ER功能降低或PR基因表达过少。我们将统计数据集按照PR浓度大致相同进行分组,以便更有力地判断该比值,因为PR几乎不会随年龄变化(与不稳定的ER不同)。我们在对147例患者进行放射受体分析时采用了这种按PR分组的方法。1)老年患者的ER/PR商值较高,但主要是高PR患者的该比值比低PR患者低约10倍。这就是为什么在未校正的情况下判断某患者的ER与PR相比是否过高或过低时可能会出现超过10倍的误差。这意味着,例如,对于任何一位患者,仅在其PR分组范围内(并考虑年龄)比较其ER/PR,才有可能推断ER是否过度产生。这对治疗和预后可能很重要。2)在PR分组中,ER和ER/PR的个体差异比整个统计数据集小约10倍。这就是为什么例如PR分组中ER和ER/PR随年龄增加的相关系数比未分层的整个统计数据集更有利。如果某些作者认为在较高年龄时PR会降低,那么就需要以另一种方式创建PR分组。例如,每个年龄组中PR最高的20%的肿瘤将归为同一PR分组(尽管它们的PR不同)。年龄对ER/PR的影响将比仅对ER的影响更明显,因为分子升高而分母降低。基于同样的原理,可能更灵敏地检测到卵巢周期的影响。通过这种方式,可以分析将受体结果转换为平均年龄或排卵周期最佳阶段的可能性,以防止例如ER的假阴性。这种数学方法的原理甚至可用于仅根据一种激素不同亚型受体的相互比值(ERα/ERβ或PRA/PRB)来判断预后和治疗。这不仅涉及乳腺癌,还涉及子宫癌。

相似文献

1
Ratio of concentrations of estrogen receptors to progesterone receptors (ER/PR) in the cytosol of breast cancers (stratification by forming of groups differing in PR).乳腺癌细胞溶质中雌激素受体与孕激素受体浓度之比(按孕激素受体不同分组分层)。
Neoplasma. 2007;54(4):290-6.
2
Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?雌激素受体β——雌激素受体α和孕激素受体阳性乳腺癌的独立预后标志物?
APMIS. 2009 Sep;117(9):644-50. doi: 10.1111/j.1600-0463.2009.02510.x.
3
Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.激素和HER-2受体对原发性早期乳腺癌初次手术后的短期预后
Breast Cancer Res Treat. 2009 May;115(2):349-58. doi: 10.1007/s10549-008-0110-6. Epub 2008 Jul 16.
4
[Demonstration of the effect of estrogen and progesterone receptors on survival in breast cancer without cytostatic and hormonal treatment in a small set of patients].[在一小部分患者中,无细胞抑制和激素治疗情况下雌激素和孕激素受体对乳腺癌生存影响的论证]
Klin Onkol. 2010;23(1):25-33.
5
Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.使用定量氟-18氟脱氧葡萄糖/正电子发射断层扫描成像参数比较三阴性乳腺癌与雌激素受体阳性/孕激素受体阳性/人表皮生长因子受体2阴性乳腺癌:一种对疾病特征描述可能有用的方法。
Cancer. 2008 Mar 1;112(5):995-1000. doi: 10.1002/cncr.23226.
6
Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.雌激素受体和孕激素受体肿瘤表达在丹麦卵巢癌患者中的预后价值:来自“MALOVA”卵巢癌研究
Oncol Rep. 2007 Nov;18(5):1051-9.
7
Biochemically estrogen receptor-negative, progesterone receptor-positive breast carcinoma. Immunocytochemical hormone receptors and prognostic factors.生物化学雌激素受体阴性、孕激素受体阳性乳腺癌。免疫细胞化学激素受体与预后因素。
Arch Pathol Lab Med. 1994 Mar;118(3):240-4.
8
Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.巴基斯坦北部乳腺癌的形态学特征及HER-2/neu与预后标志物的关联
J Coll Physicians Surg Pak. 2009 Feb;19(2):99-103.
9
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.包括雌激素受体(ER)、孕激素受体(PR)、Bcl-2和胰岛素样生长因子-1受体(IGF-IR)在内的雌激素受体活性谱,可能有潜力作为晚期乳腺癌患者来曲唑或他莫昔芬治疗的选择标准。
Acta Oncol. 2009;48(4):522-31. doi: 10.1080/02841860802676383.
10
Estrogen and progesterone hormone receptor status in breast carcinoma: comparison of immunocytochemistry and immunohistochemistry.乳腺癌中雌激素和孕激素受体状态:免疫细胞化学与免疫组织化学的比较
Indian J Cancer. 2010 Apr-Jun;47(2):148-50. doi: 10.4103/0019-509X.63006.